Please login to the form below

Not currently logged in
Email:
Password:

priority review

This page shows the latest priority review news and features for those working in and with pharma, biotech and healthcare.

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’ s Genetech nabs speedy review for Tecentriq in first-line breast cancer. ... Roche could soon see Tecentriq become part of the first immunotherapy combination approved to treat triple-negative breast cancer, after gaining a priority review from

Latest news

More from news
Approximately 5 fully matching, plus 272 partially matching documents found.

Latest Intelligence

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Lastly, AZ has also gained three Breakthrough Therapy Designations (including two Orphan Drug Designations) and six additional Priority Review Designations.

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA) ’s Priority Review pathway, ... This means the out-of-pocket cost for healthcare has fallen,

  • Pharma deals continue to slide Pharma deals continue to slide

    Gilead has been trying to diversify away from anti-viral therapies into oncology and Kite is a good fit with its CAR-T technology and a lead product in priority review ... Headline. $m. Kite (US). Gilead (US). Company acquisition. CAR-T technology with

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Expedited drug development and nonstandard review approval pathways are the new norm in the US, but in the EU special approval procedures are not as common. ... In 2016 special approval pathways and designations like Fast Track, Breakthrough, Accelerated

  • Deal Watch February 2017 Deal Watch February 2017

    Large pharma out-licensing. In our Annual Review of deals for 2016 we noted that AstraZeneca was the most active large pharma in divesting non-core assets. ... Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • The Heart of the Matter 7: Reality Dawns

    As patient-centricity becomes embedded as a key priority for payers and providers, greater emphasis is being placed on real-world data and how it can be used to measure clinical ... Similarly, we also leveraged real-world historical comparator data to

  • A forward march for adaptive designs

    This echoes strong positive signals this year from regulatory agencies, which included potential priority review status for IND applications whose clinical studies employ adaptive design. ... Companies submitting an IND application can now potentially

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics